Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Earnings for Tenaya Therapeutics, Inc. (TNYA)
Earnings in 2023 (TTM): $-124,084,000
According to Tenaya Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-124,084,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Tenaya Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-124,084,000 | $-124,084,000 |
| 2022 | $-123,665,000 | $-123,663,044 |
| 2021 | $-72,721,000 | $-69,652,000 |
| 2020 | $-38,395,000 | $-38,308,000 |
| 2019 | $-26,231,000 | $-25,778,000 |